CCM
SLXNW

Context Capital Management’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Context Capital Management’s Portfolio SLXNW Stock Details SLXNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56K Hold
51,183
– – ﹤0.01% 417
2026
Q1 		$1.04K Hold
51,183
– – ﹤0.01% 389
2025
Q4 		$1.33K Hold
51,183
– – ﹤0.01% 322
2025
Q3 		$1.8K Hold
51,183
– – ﹤0.01% 263
2025
Q2 		$2.09K Hold
51,183
– – ﹤0.01% 242
2025
Q1 		$3.92K Hold
51,183
– – ﹤0.01% 192
2024
Q4 		$1.74K Sell
51,183
-11,055
-18% -$444 ﹤0.01% 216
2024
Q3 		$1.97K Buy
+62,238
New +$3.6K ﹤0.01% 266

Other funds holding SLXNW

SBLIC
Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $2.18M AUM 50.81% 1-Year Est. Return

Context Capital Management's SLXNW Position: Q2 2026 in Review

Context Capital Management held its Silexion Therapeutics Warrant (SLXNW) position steady in Q2 2026 at 51,183 shares worth $1.56K. The position accounts for ﹤0.01% of the portfolio, ranked #417.

Context Capital Management first reported a position in SLXNW in Q3 2024 and has held it in 8 quarters since. The position peaked at $3.92K in Q1 2025. 3 funds tracked by Wall St. Rank hold SLXNW as of Q2 2026.

  • Context Capital Management held 51,183 shares of Silexion Therapeutics Warrant worth $1.56K as of Q2 2026.
  • Context Capital Management left its Silexion Therapeutics Warrant share count unchanged in Q2 2026.
  • Silexion Therapeutics Warrant made up ﹤0.01% of Context Capital Management's portfolio in Q2 2026, its #417 holding.
  • Context Capital Management first reported a position in Silexion Therapeutics Warrant in Q3 2024 and has held it in 8 quarters since.
  • Context Capital Management's Silexion Therapeutics Warrant position peaked at $3.92K in Q1 2025.
  • 3 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q2 2026.

Based on Context Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.